Voloridge Investment Management LLC Purchases 515,836 Shares of Pfizer Inc. (NYSE:PFE)

Voloridge Investment Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 27.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,402,685 shares of the biopharmaceutical company’s stock after buying an additional 515,836 shares during the quarter. Voloridge Investment Management LLC’s holdings in Pfizer were worth $63,743,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PFE. Parsons Capital Management Inc. RI lifted its stake in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after acquiring an additional 159,984 shares in the last quarter. Mcdonald Partners LLC lifted its stake in Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after acquiring an additional 9,963 shares in the last quarter. Bank of Jackson Hole Trust bought a new position in Pfizer during the 4th quarter valued at $264,000. Amplius Wealth Advisors LLC lifted its stake in Pfizer by 80.7% during the 4th quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company’s stock valued at $1,242,000 after acquiring an additional 20,911 shares in the last quarter. Finally, Harvey Capital Management Inc. bought a new position in Pfizer during the 4th quarter valued at $544,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on PFE shares. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Trading Up 2.2%

Shares of PFE opened at $23.51 on Wednesday. The business has a 50-day moving average of $23.56 and a 200 day moving average of $25.27. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The firm has a market cap of $133.66 billion, a P/E ratio of 16.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm posted $0.82 EPS. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.32%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.